Fluid OverloadTIDENCT07275658
Timing and Dose of Fluid Deresuscitation in Critically Ill Patients
An observational study of Fluid Overload and Critical Care, Intensive Care, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 2 sites in Netherlands.
Trial summary
Fluid deresuscitation is an important intervention in the Intensive Care Unit (ICU). This study aims to find (1) determinants of successful deresuscitation, (2) the optimal rate (dose) of deresuscitation based on these determinants, and (3) differences in metabolic profiles for a more personalized approach of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fluid Overload, Critical Care, Intensive Care, Deresuscitation
- How many people
- 150 participants
- Where
- 2 sitesNetherlands
- Study dates
- 15 Oct 2025to 28 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients admitted to the Intensive Care Unit
Who may be able to join
- Admission to one of the participating ICUs;
- Clinical indication for deresuscitation using diuretics or ultrafiltration as set by the treating physician; first attempt during the ICU stay.
Who cannot join
- Age below 18 years old;
- Major cardiac shunts;
- Moderate to severe aortic regurgitation;
- Morbid Obesisty (BMI >40);
- POCUS impossible or unreliable (i.e. pre-existing interstitial lung disease);
- PLR or modified form of PLR impossible (i.e. ECMO);
Show all 10Show fewer
- Transfer from another ICU;
- Previous inclusion in this study;
- Patients who are moribund or facing the end of life;
- Opt out.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Santje A.S. Slot, MD contact
Netherlands2 sites, 2 recruiting
- Recruiting
OLVG
Amsterdam, 1091AC
Santje A.S. Slot, MD, +31 (0)20 599 9111, s.a.s.slot@olvg.nl
- Recruiting
Amsterdam UMC
Amsterdam, 1105AZ
Krijna Opschoor, MD, +31 (0)20 566 9111, k.opschoor@amsterdamumc.nl
About this study
Official title: Timing and Dose of Fluid Deresuscitation in Critically Ill Patients: a Prospective Observational Multicenter Study
Fluid deresuscitation is an important intervention in the Intensive Care Unit (ICU). This study aims to find (1) determinants of successful deresuscitation, (2) the optimal rate (dose) of deresuscitation based on these determinants, and (3) differences in metabolic profiles for a more personalized approach of deresuscitation.
This study is a multicenter, prospective, observational cohort study in critically ill patients. This study will include ICU patients who have a clinical indication for deresuscitation as set by the treating physician. Clinical, ultrasound and laboratory values will be collected and used for analysis.
Read the detailed description
Primary objective:
The aim of this study is to identify determinants of successful deresuscitation in ICU patients, defined as achieving a negative fluid balance within 24 hours without hemodynamic consequences.
Secondary objectives:
- Timing of deresuscitation:
- Identify determinants of successful deresuscitation in ICU patients, defined as achieving a negative fluid balance within 24 hours;
- Compare these determinants with determinants for the clinical decision of deresuscitation by the treating physician;
- Identify differences in these determinants within subgroups of sepsis, ARDS and cardiac patients, provided the numbers are sufficient;
- Rate (dose) of deresuscitation:
- Identify parameters associated with diuretic or natriuretic response during deresuscitation;
- Find individualized optimal rates of deresuscitation based on these determinants;
- Possible complications of deresuscitation:
- Determine whether there is an association between electrolyte or acid-base disturbances during deresuscitation (e.g. the Strong Ion Difference) and clinical outcomes;
- Determine whether there is an association between the rate of deresuscitation and hemodynamic consequences;
- Determine whether there is an association between the timing and rate of deresuscitation and atrial fibrillation (AF);
- Determine whether there is an association between deresuscitation and the occurrence of delirium;
- Determine whether there is an association between timing and rate of deresuscitation and acute kidney injury (AKI).
Study design:
The TIDE study is a multicenter, prospective, observational cohort study in the ICUs of the Amsterdam UMC and OLVG in Amsterdam, the Netherlands.
Study population:
Adult patients admitted to the ICU, who have a clinical indication for deresuscitation as set by the treating physician, using diuretics or ultrafiltration; first deresuscitation attempt during the ICU stay.
Sample size calculation:
For finding associations with logistic regression with a moderate (odds ratio >1.5) to strong (odds ratio >2.5) effect an alpha set at 0.05, power set at 0.8 and an estimated failure of 50% or more, we would need a sample size of around 150-210 patients.
Methods:
Patients in the participating ICUs are screened for eligibility when the treating physician sets a clinical indication for deresuscitation. Eligible patients will be included in the study. At that time, defined as baseline, clinical, ultrasound and laboratory measures will be collected. Clinical measures among others include: heart rate, mean arterial pressure, dose of vasopressors, and capillary refill time. Ultrasound measurements include: lung ultrasound scores (LUS), venous excess ultrasound (VExUS), and cardiac ultrasound, including VTI during a passive leg raise (PLR). Laboratory measurements include arterial blood gas analysis and urinalysis. Furthermore, baseline characteristics such as demographics, reason for ICU admission, severity of illness scores, and medical history are collected.
Deresuscitation will be performed according to standard care according to the treating physician's insights. Primary follow up is 24 hours in which granular data of deresuscitation tactics, deresuscitation output, electrolyte and acid-base disturbances, and hemodynamic consequences are collected. Secondary follow up is at 7 days for complications such as acute kidney injury and at 28 days for mortality, ICU length of stay (LOS) and ventilator free days (VFD), where available.
- Keywords
- ultrasound, RRT, furosemide
- Medical subject headings
- Edema
What is being measured
The primary outcome is the main question the study is designed to answer.
Successful deresuscitation without hemodynamic consequences
Reach negative fluid balance in first 24 hours without hemodynamic consequences (yes/no), defined as either hypotension or hypoperfusion:
- Hypotension
- Interventions required to maintain blood pressure MAP > 65mmHg
- Deresuscitation is stopped
- Fluid bolus needs to be given
- Noradrenaline (or other vasopressor) needs to be initiated, increased to > 0.2 microg/kg/min, or increased by 50%
- Dose reduction or interruption of RRT
- Hypoperfusion (one of the following):
- Arterial lactate level >3 and/or increased 25% or more
- New development of mottled skin
- Capillary refill time > 3 seconds
- New oliguria (urine output < 0.3-0.5ml/kg/hour for the previous 6 hours)
Measured: 24 hours
Secondary outcomes (16)
Successful deresuscitation
Reach negative fluid balance in the first 24 hours
Measured: 24 hours
Rate of deresuscitation
Urine output or ultrafiltration rate in mL/kg/h
Measured: 24 hours
Dose of deresuscitation
Fluid balance in mL/kg
Measured: 24 hours
Natriuresis
Urinary sodium output in mmol/L/24h
Measured: 24 hours
Delta Strong Ion Difference
ΔSID in mmol/L
Measured: 24 hours
Delta serum sodium
Serum ΔNa in mmol/L
Measured: 24 hours
Delta serum chloride
Serum ΔCl in mmol/L
Measured: 24 hours
Atrial fibrillation
Occurrence of ≥1 hour AF or AF for which treatment is needed during the deresuscitation window if not present at baseline
Measured: 24 hours
Acute Kidney Injury (AKI)
AKI as diagnosed based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria:
Stage 1: sCreat 1.5-1.9 times baseline OR ≥0.3 mg/dl (≥26.5 mmol/l) increase OR urine output <0.5 ml/kg/h for 6-12 hours Stage 2: sCreat 2.0-2.9 times baseline OR urine output <0.5 ml/kg/h for ≥12 hours Stage 3: sCreat 3.0 times baseline OR Increase in serum creatinine to ≥4.0 mg/dl (X353.6 mmol/l) OR Initiation of renal replacement therapy OR urine output <0.3 ml/kg/h for ≥24 hours OR anuria for ≥ 12 hours
Measured: 7 days
Persistent AKI
Prolonged AKI for ≥48 hours if not present before start deresuscitation
Measured: 7 days
Renal Replacement Therapy (RRT)
Need for RRT after start deresuscitation if not used at baseline and primary deresuscitation
Measured: 7 days
Delirium
Need 1 or more types of medication to treat delirium after start deresuscitation
Measured: 7 days
ICU-mortality
Mortality within ICU stay
Measured: 28 days
28-day mortality
Mortality after 28 days
Measured: 28 days
Ventilator free days (VFD)
Patient is alive and breathes without assistance of the mechanical ventilator, if the period of unassisted breathing lasted at least 24 consecutive hours:
- VFD-28 = 0 if subject dies within 28 days of mechanical ventilation
- VFD-28 = 28 - x if successfully liberated from ventilation x days after initiation successful liberation: extubation (planned or unplanned) without death or reintubation within the next 72 hours
- VFD-28 = 0 if the subject is mechanically ventilated for ≥ 28 days
Measured: 28 days
ICU length of stay (LOS)
Length of stay in the intensive care unit
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2025
- Study start15 Oct 2025
- Primary completion31 Jan 2027 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fluid OverloadStudies of the same condition, open and under way.
- More trials run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- OLVG
- Responsible party
- Principal investigator, P.R. Tuinman, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07275658
- Sponsor's protocol ID
- 2025.0391
- Acronym
- TIDE
- Status last verified
- Nov 2025
- First submitted
- 28 Nov 2025
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Timing and Dose of Fluid Deresuscitation in Critically Ill Patients: a Prospective Observational Multicenter Study
- ClinicalTrials.gov ID
- NCT07275658
- Acronym / sponsor ID
- TIDE / 2025.0391
- Keywords
- ultrasound, RRT, furosemide
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)University, hospital or other
- Collaborators
- OLVG
- Study start
- 15 Oct 2025 (actual)
- Primary completion
- 31 Jan 2027 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 10 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fluid deresuscitation is an important intervention in the Intensive Care Unit (ICU). This study aims to find (1) determinants of successful deresuscitation, (2) the optimal rate (dose) of deresuscitation based on these determinants, and (3) differences in metabolic profiles for a more personalized approach of deresuscitation.
This study is a multicenter, prospective, observational cohort study in critically ill patients. This study will include ICU patients who have a clinical indication for deresuscitation as set by the treating physician. Clinical, ultrasound and laboratory values will be collected and used for analysis.
Detailed description
Primary objective:
The aim of this study is to identify determinants of successful deresuscitation in ICU patients, defined as achieving a negative fluid balance within 24 hours without hemodynamic consequences.
Secondary objectives:
- Timing of deresuscitation:
- Identify determinants of successful deresuscitation in ICU patients, defined as achieving a negative fluid balance within 24 hours;
- Compare these determinants with determinants for the clinical decision of deresuscitation by the treating physician;
- Identify differences in these determinants within subgroups of sepsis, ARDS and cardiac patients, provided the numbers are sufficient;
- Rate (dose) of deresuscitation:
- Identify parameters associated with diuretic or natriuretic response during deresuscitation;
- Find individualized optimal rates of deresuscitation based on these determinants;
- Possible complications of deresuscitation:
- Determine whether there is an association between electrolyte or acid-base disturbances during deresuscitation (e.g. the Strong Ion Difference) and clinical outcomes;
- Determine whether there is an association between the rate of deresuscitation and hemodynamic consequences;
- Determine whether there is an association between the timing and rate of deresuscitation and atrial fibrillation (AF);
- Determine whether there is an association between deresuscitation and the occurrence of delirium;
- Determine whether there is an association between timing and rate of deresuscitation and acute kidney injury (AKI).
Study design:
The TIDE study is a multicenter, prospective, observational cohort study in the ICUs of the Amsterdam UMC and OLVG in Amsterdam, the Netherlands.
Study population:
Adult patients admitted to the ICU, who have a clinical indication for deresuscitation as set by the treating physician, using diuretics or ultrafiltration; first deresuscitation attempt during the ICU stay.
Sample size calculation:
For finding associations with logistic regression with a moderate (odds ratio >1.5) to strong (odds ratio >2.5) effect an alpha set at 0.05, power set at 0.8 and an estimated failure of 50% or more, we would need a sample size of around 150-210 patients.
Methods:
Patients in the participating ICUs are screened for eligibility when the treating physician sets a clinical indication for deresuscitation. Eligible patients will be included in the study. At that time, defined as baseline, clinical, ultrasound and laboratory measures will be collected. Clinical measures among others include: heart rate, mean arterial pressure, dose of vasopressors, and capillary refill time. Ultrasound measurements include: lung ultrasound scores (LUS), venous excess ultrasound (VExUS), and cardiac ultrasound, including VTI during a passive leg raise (PLR). Laboratory measurements include arterial blood gas analysis and urinalysis. Furthermore, baseline characteristics such as demographics, reason for ICU admission, severity of illness scores, and medical history are collected.
Deresuscitation will be performed according to standard care according to the treating physician's insights. Primary follow up is 24 hours in which granular data of deresuscitation tactics, deresuscitation output, electrolyte and acid-base disturbances, and hemodynamic consequences are collected. Secondary follow up is at 7 days for complications such as acute kidney injury and at 28 days for mortality, ICU length of stay (LOS) and ventilator free days (VFD), where available.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients admitted to the Intensive Care Unit
Key inclusion criteria (2 listed)
- Admission to one of the participating ICUs;
- Clinical indication for deresuscitation using diuretics or ultrafiltration as set by the treating physician; first attempt during the ICU stay.
Key exclusion criteria (10 listed)
- Age below 18 years old;
- Major cardiac shunts;
- Moderate to severe aortic regurgitation;
- Morbid Obesisty (BMI >40);
- POCUS impossible or unreliable (i.e. pre-existing interstitial lung disease);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Successful deresuscitation without hemodynamic consequences
Time frame: 24 hours
Reach negative fluid balance in first 24 hours without hemodynamic consequences (yes/no), defined as either hypotension or hypoperfusion: 1. Hypotension * Interventions required to maintain blood pressure MAP > 65mmHg * Deresuscitation is stopped * Fluid bolus needs to be given * Noradrenaline (or other vasopressor) needs to be initiated, increased to > 0.2 microg/kg/min, or increased by 50% * Dose reduction or interruption of RRT 2. Hypoperfusion (one of the following): * Arterial lactate level >3 and/or increased 25% or more * New development of mottled skin * Capillary refill time > 3 seconds * New oliguria (urine output < 0.3-0.5ml/kg/hour for the previous 6 hours)
16 secondary outcomes
Successful deresuscitation
Time frame: 24 hours
Rate of deresuscitation
Time frame: 24 hours
Dose of deresuscitation
Time frame: 24 hours
Natriuresis
Time frame: 24 hours
Delta Strong Ion Difference
Time frame: 24 hours
Delta serum sodium
Time frame: 24 hours
Delta serum chloride
Time frame: 24 hours
Atrial fibrillation
Time frame: 24 hours
Acute Kidney Injury (AKI)
Time frame: 7 days
Persistent AKI
Time frame: 7 days
Renal Replacement Therapy (RRT)
Time frame: 7 days
Delirium
Time frame: 7 days
ICU-mortality
Time frame: 28 days
28-day mortality
Time frame: 28 days
Ventilator free days (VFD)
Time frame: 28 days
ICU length of stay (LOS)
Time frame: 28 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
Related trials for Fluid Overload
Recruiting
Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure
Acute Kidney Injury, Fluid Overload
Recruiting
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
Chronic Heart Failure, CKD Stage 3
Not yet recruitingPhase 4
Capital Offload-Shock
Hypervolemia, Cardiogenic Shock
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Not yet recruiting
Bioimpedance and Multiparametric Ultrasound-Guided Fluid Management After Kidney Transplantation
Kidney Transplantation, Delayed Graft Function
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Santje A.S. Slot, MD contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fluid Overload and Critical Care, Intensive Care, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 2 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Krijna Opschoor, MD (+31 (0)20 566 9111, k.opschoor@amsterdamumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Successful deresuscitation without hemodynamic consequences (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.